289.96
price up icon0.33%   0.96
after-market Handel nachbörslich: 283.25 -6.71 -2.31%
loading
Schlusskurs vom Vortag:
$289.00
Offen:
$286.385
24-Stunden-Volumen:
756.86K
Relative Volume:
0.78
Marktkapitalisierung:
$37.81B
Einnahmen:
$2.35B
Nettoeinkommen (Verlust:
$-269.70M
KGV:
-138.74
EPS:
-2.09
Netto-Cashflow:
$-75.39M
1W Leistung:
+1.63%
1M Leistung:
+19.83%
6M Leistung:
+18.40%
1J Leistung:
+94.11%
1-Tages-Spanne:
Value
$284.19
$291.22
1-Wochen-Bereich:
Value
$284.19
$298.23
52-Wochen-Spanne:
Value
$146.79
$304.39

Alnylam Pharmaceuticals Inc Stock (ALNY) Company Profile

Name
Firmenname
Alnylam Pharmaceuticals Inc
Name
Telefon
(617) 551-8200
Name
Adresse
675 WEST KENDALL STREET, CAMBRIDGE, MA
Name
Mitarbeiter
2,230
Name
Twitter
@alnylam
Name
Nächster Verdiensttermin
2024-10-31
Name
Neueste SEC-Einreichungen
Name
ALNY's Discussions on Twitter

Vergleichen Sie ALNY mit anderen Aktien

Aktien Preis Marktkapitalisierung Umsatz Nettogewinn Free Cashflow ENV
Biotechnology icon
ALNY
Alnylam Pharmaceuticals Inc
289.96 37.20B 2.35B -269.70M -75.39M -2.09
Biotechnology icon
ONC
Beigene Ltd Adr
241.43 27.03B 3.81B -644.79M -669.77M -6.24
Biotechnology icon
VRTX
Vertex Pharmaceuticals Inc
436.00 112.64B 11.10B -988.90M -1.26B -3.92
Biotechnology icon
AKTX
Akari Therapeutics Plc Adr
1.335 40.86M 0 0 0 0.00
Biotechnology icon
REGN
Regeneron Pharmaceuticals Inc
588.34 64.17B 14.09B 4.50B 2.96B 39.28
Biotechnology icon
VRNA
Verona Pharma Plc Adr
75.06 6.07B 0 -153.72M -103.81M -2.00

Alnylam Pharmaceuticals Inc Stock (ALNY) Upgrades & Downgrades

Datum Aktion Analytiker Ratingänderung
2025-03-31 Eingeleitet Redburn Atlantic Buy
2025-03-24 Hochstufung JP Morgan Neutral → Overweight
2024-11-12 Herabstufung Wolfe Research Peer Perform → Underperform
2024-10-16 Eingeleitet Scotiabank Sector Outperform
2024-08-16 Hochstufung Goldman Neutral → Buy
2024-02-16 Herabstufung Goldman Buy → Neutral
2024-02-15 Eingeleitet Wolfe Research Peer Perform
2023-12-08 Eingeleitet Wells Fargo Equal Weight
2023-10-11 Herabstufung Oppenheimer Outperform → Perform
2023-09-29 Eingeleitet Raymond James Outperform
2023-05-05 Hochstufung BMO Capital Markets Market Perform → Outperform
2023-04-26 Eingeleitet SMBC Nikko Neutral
2023-03-21 Eingeleitet Bernstein Outperform
2023-01-18 Eingeleitet Canaccord Genuity Buy
2022-09-09 Fortgesetzt Morgan Stanley Equal-Weight
2022-07-13 Eingeleitet Cantor Fitzgerald Neutral
2022-06-27 Herabstufung Guggenheim Buy → Neutral
2022-06-07 Eingeleitet William Blair Outperform
2022-04-25 Herabstufung Morgan Stanley Overweight → Equal-Weight
2022-03-01 Eingeleitet Citigroup Buy
2022-02-03 Hochstufung Guggenheim Neutral → Buy
2022-01-03 Hochstufung Piper Sandler Neutral → Overweight
2021-11-22 Hochstufung Goldman Neutral → Buy
2021-11-22 Hochstufung RBC Capital Mkts Sector Perform → Outperform
2021-11-01 Hochstufung Oppenheimer Perform → Outperform
2021-10-04 Hochstufung UBS Neutral → Buy
2021-08-04 Herabstufung Piper Sandler Overweight → Neutral
2021-02-22 Herabstufung Guggenheim Buy → Neutral
2021-02-12 Herabstufung Citigroup Buy → Neutral
2021-02-12 Bestätigt H.C. Wainwright Buy
2021-01-25 Herabstufung BMO Capital Markets Outperform → Market Perform
2020-09-30 Fortgesetzt Berenberg Hold
2020-09-08 Eingeleitet Citigroup Buy
2020-08-11 Herabstufung Oppenheimer Outperform → Perform
2020-05-13 Eingeleitet RBC Capital Mkts Sector Perform
2020-05-07 Herabstufung JP Morgan Overweight → Neutral
2020-04-24 Fortgesetzt Evercore ISI Outperform
2020-03-19 Eingeleitet Berenberg Buy
2019-12-19 Bestätigt Chardan Capital Markets Buy
2019-11-20 Eingeleitet Oppenheimer Outperform
2019-11-13 Eingeleitet BofA/Merrill Buy
2019-05-23 Fortgesetzt Goldman Neutral
2019-04-12 Eingeleitet Evercore ISI Outperform
2019-03-06 Hochstufung Evercore ISI In-line → Outperform
2019-03-05 Hochstufung Morgan Stanley Equal-Weight → Overweight
2019-01-23 Eingeleitet UBS Neutral
2018-10-01 Eingeleitet Cantor Fitzgerald Overweight
2018-08-13 Bestätigt Stifel Buy
2018-08-07 Hochstufung Stifel Hold → Buy
2018-05-04 Bestätigt Stifel Hold
2018-03-28 Eingeleitet Evercore ISI In-line
Alle ansehen

Alnylam Pharmaceuticals Inc Aktie (ALNY) Neueste Nachrichten

pulisher
May 24, 2025

3 High-Flying Stocks That Could Soar Even More - AOL.com

May 24, 2025
pulisher
May 22, 2025

Huntington's Disease Pipeline 2025: Groundbreaking Clinical - openPR.com

May 22, 2025
pulisher
May 21, 2025

Alnylam Issues 2024 Corporate Responsibility Report - BioSpace

May 21, 2025
pulisher
May 20, 2025

Alnylam Issues 2024 Corporate Responsibility Report | ALNY Stock News - GuruFocus

May 20, 2025
pulisher
May 19, 2025

Alnylam posts new Phase 3 data for heart disease therapy Amvuttra - MSN

May 19, 2025
pulisher
May 19, 2025

Alnylam (ALNY) Highlights Promising HELIOS-B Study Results at He - GuruFocus

May 19, 2025
pulisher
May 18, 2025

Alnylam (ALNY) Highlights Promising HELIOS-B Study Results at Heart Failure 2025 Congress | ALNY Stock News - GuruFocus

May 18, 2025
pulisher
May 18, 2025

Alnylam Q1 Earnings Beat Estimates, Product Revenues Rise Y/Y - MSN

May 18, 2025
pulisher
May 17, 2025

Alnylam (ALNY) Reports Positive Long-Term Data for Amvuttra in C - GuruFocus

May 17, 2025
pulisher
May 17, 2025

Alnylam posts new data for heart disease drug (ALNY:NASDAQ) - Seeking Alpha

May 17, 2025
pulisher
May 17, 2025

AMVUTTRA® (vutrisiran) Significantly Reduces Mortality and a Range of Important Cardiovascular Events in Patients with ATTR Amyloidosis with Cardiomyopathy: Additional Data from HELIOS-B - Business Wire

May 17, 2025
pulisher
May 16, 2025

High Growth US Tech Stocks To Watch In May 2025 - simplywall.st

May 16, 2025
pulisher
May 15, 2025

Cardiac amyloidosis Pipeline 2025: Groundbreaking Clinical - openPR.com

May 15, 2025
pulisher
May 14, 2025

Promoting A Newly Approved Indication Against Established Competitors - Life Science Leader

May 14, 2025
pulisher
May 14, 2025

Alnylam Halts Patent Row Over Pfizer, BioNTech COVID-19 Vax - Law360

May 14, 2025
pulisher
May 14, 2025

Alnylam drops Covid vaccine patent case against Pfizer, BioNTech for now - Reuters

May 14, 2025
pulisher
May 14, 2025

Alnylam shareholders approve executive compensation plan By Investing.com - Investing.com Canada

May 14, 2025
pulisher
May 13, 2025

Alnylam Pharmaceuticals, Inc. (ALNY): Among the Best Growth Stocks to Buy and Hold for the Long Term - Yahoo

May 13, 2025
pulisher
May 13, 2025

Alnylam shareholders approve executive compensation plan - Investing.com

May 13, 2025
pulisher
May 13, 2025

Alnylam Pharma Re-elects Directors at Annual Meeting - TipRanks

May 13, 2025
pulisher
May 13, 2025

12 Best Growth Stocks to Buy and Hold for the Long Term - Insider Monkey

May 13, 2025
pulisher
May 13, 2025

Hypercholesterolemia Treatment Market Top Companies Study - openPR.com

May 13, 2025
pulisher
May 13, 2025

Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) Receives $319.17 Consensus Target Price from Analysts - Defense World

May 13, 2025
pulisher
May 12, 2025

Alnylam Pharmaceuticals (NasdaqGS:ALNY) To Present Pivotal TTR Franchise Data At Heart Failure Congress - simplywall.st

May 12, 2025
pulisher
May 12, 2025

Alnylam to present key data on amyloidosis treatments By Investing.com - Investing.com South Africa

May 12, 2025
pulisher
May 12, 2025

Alnylam Pharmaceuticals, Inc.'s (NASDAQ:ALNY) Path To Profitability - Yahoo Finance

May 12, 2025
pulisher
May 12, 2025

Alnylam (ALNY) to Unveil Latest Transthyretin Amyloidosis Data a - GuruFocus

May 12, 2025
pulisher
May 12, 2025

Alnylam To Share Progress Across Its Transthyretin Amyloidosis Franchise Including Additional Analyses Of The Helios-B Phase 3 Study Results At Heart Failure 2025 Congress - marketscreener.com

May 12, 2025
pulisher
May 12, 2025

Alnylam to Share Progress Across its Transthyretin Amyloidosis F - GuruFocus

May 12, 2025
pulisher
May 12, 2025

Alnylam to present key data on amyloidosis treatments - Investing.com Australia

May 12, 2025
pulisher
May 12, 2025

Alnylam to Share Progress Across its Transthyretin Amyloidosis Franchise Including Additional Analyses of the HELIOS-B Phase 3 Study Results at Heart Failure 2025 Congress - Business Wire

May 12, 2025
pulisher
May 10, 2025

Trend Tracker for (ALNY) - news.stocktradersdaily.com

May 10, 2025
pulisher
May 09, 2025

‘Our bodies are art’: Alnylam campaign uses dance to tell patient’s story - Medical Marketing and Media

May 09, 2025
pulisher
May 09, 2025

Alnylam Announces FDA Approval of AMVUTTRA® (vutrisiran), the First RNAi Therapeutic to Reduce Cardiovascular Death, Hospitalizations and Urgent Heart Failure Visits in Adults with ATTR Amyloidosis with Cardiomyopathy (ATTR-CM) - Becker's Hospital Review

May 09, 2025
pulisher
May 09, 2025

RNA Therapy Market Booms Amid Advancements in mRNA and Gene - openPR.com

May 09, 2025
pulisher
May 09, 2025

Vir posts mid-stage trial data for Hep B drug (VIR:NASDAQ) - Seeking Alpha

May 09, 2025
pulisher
May 08, 2025

$100 Invested In Alnylam Pharmaceuticals 15 Years Ago Would Be Worth This Much Today - Benzinga

May 08, 2025
pulisher
May 08, 2025

LEQVIO Strengthens Position as Leader in Cholesterol-Lowering Therapies Across Seven Major Markets | DelveInsight - ADVFN

May 08, 2025
pulisher
May 08, 2025

Dysautonomia Market Forecasted to Surge in Coming Years, - openPR.com

May 08, 2025
pulisher
May 08, 2025

Porphyria Treatment Market Grows with Targeted Rare Disease - openPR.com

May 08, 2025
pulisher
May 08, 2025

Alnylam keeps pushing the rare disease paradigm as RNAi promises even wider indications - Pharma Voice

May 08, 2025
pulisher
May 08, 2025

Possible Bearish Signals With Alnylam Pharmaceuticals Insiders Disposing Stock - Yahoo Finance

May 08, 2025
pulisher
May 08, 2025

Alnylam Pharmaceuticals (NASDAQ:ALNY) Upgraded to “Buy” at StockNews.com - Defense World

May 08, 2025
pulisher
May 07, 2025

U.S. Transthyretin Amyloidosis Treatment Market Set to Witness - openPR.com

May 07, 2025
pulisher
May 07, 2025

Coagulation factor deficiency Market: Epidemiology, - openPR.com

May 07, 2025
pulisher
May 06, 2025

Alnylam Pharmaceuticals First Quarter 2025 Earnings: Beats Expectations - simplywall.st

May 06, 2025

Finanzdaten der Alnylam Pharmaceuticals Inc-Aktie (ALNY)

Umsatz

loading

Nettogewinn

loading

Free Cashflow

loading

ENV

loading
$4.25
price up icon 0.48%
$587.61
price up icon 1.06%
$31.32
price down icon 3.63%
$1.15
price down icon 17.27%
$75.06
price up icon 3.26%
Kapitalisierung:     |  Volumen (24h):